Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Anavex Life Sciences Corp

Current price
4.07 USD -0.13 USD (-3.10%)
Last closed 4.12 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 352 673 312 USD
Yield for 12 month -49.88 %
21.11.2021 - 28.11.2021

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. Address: 630 5th Avenue, New York, NY, United States, 10111

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

34.67 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures AVXL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Operating Margin TTM
PE Ratio
Return On Assets TTM -20.7 %
PEG Ratio
Return On Equity TTM -31.88 %
Wall Street Target Price 34.67 USD
Revenue TTM
Book Value 1.65 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.54 USD
Diluted Eps TTM -0.54 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AVXL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AVXL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:4
Payout Ratio
Last Split Date 07.10.2015
Dividend Date

Stock Valuation AVXL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -4.9192
Price Book MRQ 2.6013

Financials AVXL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AVXL

For 52 weeks

4.16 USD 10.45 USD
50 Day MA 5.13 USD
Shares Short Prior Month 19 998 803
200 Day MA 6.74 USD
Short Ratio 15.63
Shares Short 22 117 935
Short Percent 27.82 %

Dynamics of changes in the value of assets




411.84 USD Microsoft Corporation -5.76 (-1.38%)
Detailed analytics

ETF funds



208.40 CHF iShares MDAX UCITS ETF (DE) -12.16 (-5.06%)
Detailed analytics



2205.6 USD Gold +35.66 (+1.64%)
Detailed analytics